Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TrkA


Brief Information

Name:Nerve growth factor receptor Trk-A
Target Synonym:NTRK1,Neurotrophic tyrosine kinase receptor type 1,TRK1-transforming tyrosine kinase protein,Tyrosine kinase receptor A,TRKA,Trk-A,Tyrosine kinase receptor,EC:,High Affinity Nerve Growth Factor Receptor,EC 2.7.10,Neurotrophic Receptor Tyrosine Kinase 1,Neurotrophic Tyrosine Kinase, Receptor, Type 1,Tropomyosin-Related Kinase A,P140-TrkA,Gp140trk,MTC,TRK,Oncogene TRK,EC,TRK1,Receptor, trkA
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved


Project item Indications Research phase Cooperation demands
BDA202201 Cancer pain, chemotherapy-induced neuropathic pain, Kashin-Beck disease, diabetic neuralgia, interstitial cystitis, chronic low back pain. Phase Ⅰ/Ⅱa License-out or co-development

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CHEK-ATF093-Cell-based assay

Expression analysis of human TrkA on Human TrkA (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human TrkA (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human TrkA antibody.

Synonym Name



Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand. Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival. Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Fallopian Tube Neoplasms; Esophageal adenocarcinoma; Adenoma; Thyroid Neoplasms; Lung Neoplasms; Thymoma; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Carcinoma, Islet Cell; Ovarian Neoplasms; Liver Neoplasms; Hemangiosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoid Tumor; Insulinoma; Solid tumours; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Adenoid Cystic; Glucagonoma Details
Entrectinib NMS-E628; RXDX-101; RG-6268 Approved Nerviano Medical Sciences Srl Rozlytrek, 罗圣全 Mainland China Solid tumours Roche (China) Holding Ltd 2019-06-18 Breast Neoplasms; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Hepatic Insufficiency; Colorectal Neoplasms; Brain Neoplasms; Sarcoma; Cholangiocarcinoma; Solid tumours; Central Nervous System Neoplasms; Neuroendocrine Tumors; Salivary Gland Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Ovarian Neoplasms; Skin Melanoma Details
Larotrectinib sulfate LOXO-101; ARRY-470; BAY-2757556 Approved Array Biopharma Vitrakvi, 维泰凯 Mainland China Solid tumours Bayer Healthcare Company Ltd 2018-11-26 Endometrial Neoplasms; Sarcoma, Ewing; Neuroblastoma; Sarcoma; Histiocytosis, Langerhans-Cell; Breast Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Histiocytic Sarcoma; Colorectal Neoplasms; Neoplasms, Neuroepithelial; Lung Neoplasms; Uterine Neoplasms; Osteosarcoma; Lymphoma; Lymphoma, Non-Hodgkin; Glioma; Carcinoma, Squamous Cell; Thyroid Neoplasms; Esophageal adenocarcinoma; Melanoma; Neoplasms, Germ Cell and Embryonal; Xanthogranuloma, Juvenile; Uterine Cervical Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Rectal Neoplasms; Fibrosarcoma; Rhabdomyosarcoma; Liver Neoplasms; Leukemia; Ovarian Neoplasms; Medulloblastoma; Solid tumours; Hepatoblastoma; Rhabdoid Tumor; Carcinoma, Renal Cell; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ependymoma; Stomach Neoplasms; Skin Neoplasms; Wilms Tumor; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Multiple Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AK-1830 AK-1830 Phase 1 Clinical Array Biopharma Inflammation Details
XZP-5955 XZP-5955 Phase 2 Clinical Solid tumours Details
ACD-856 ACD-856 Alzecure Pharma Ab Details
VM-902A VM-902; VM-902A Vm Discovery Details
TQB-3558 TQB-3558 Phase 1 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Solid tumours Details
SNA-125 CT-340; SNA-125 Phase 2 Clinical Sienna Biopharmaceuticals Inc, Creabilis Sa Pruritus; Psoriasis; Dermatitis, Atopic Details
VMD-928 VMD-928 Phase 1 Clinical Vm Oncology Llc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Adenoid Cystic; Mesothelioma; Prostatic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
Lestaurtinib SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 Phase 3 Clinical Kyowa Hakko Kirin Co Ltd Leukemia; Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Psoriasis; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential Details
HG-030 HG-030 Phase 1 Clinical Hitgen Inc Solid tumours Details
PBI-200 Phase 2 Clinical Pyramid Biosciences Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms Details
HH-30134 HH-30134 Phase 1 Clinical ShangHai HaiHe Biopharma Co Ltd Solid tumours; Neoplasms Details
FCN-098 FCN-098; FCN098 Phase 1 Clinical Fochon Pharmaceuticals Ltd, Fochon Pharmaceuticals Ltd Solid tumours; Neoplasms Details
BEN-2293 BEN-00002293; BEN-2293 Phase 2 Clinical Benevolentai Bio Ltd Dermatitis, Atopic Details
VC-004 VC-004; VC 004; VC004 Phase 2 Clinical Jiangsu Vcare Pharmatech Co Ltd Solid tumours; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message